VaccineOct 5, 2025

New safety test for mRNA vaccines using lung gene markers

mRNA Technology Weekly Brief ↗PubMed ↗DOI ↗

Updated Jan 19, 2026

Abstract

Body weight and white blood cell count significantly decreased in mice receiving mRNA vaccines compared to those receiving an influenza vaccine.

Fourteen out of fifteen biomarker genes were significantly upregulated in the Spikevax group compared to the influenza vaccine group.
All biomarker genes in the COMIRNATY group showed significant upregulation compared to the influenza vaccine group.
Some biomarkers were expressed at significantly higher levels in the mRNA vaccine groups than in the toxic reference influenza vaccine group.
The mRNA vaccine groups produced significantly higher levels of inflammatory cytokines compared to both the influenza and toxic reference groups.
Global gene expression analysis confirmed that most biomarkers were included in the genes upregulated following mRNA vaccination.
Novel genes with significantly increased mRNA expression levels were identified, indicating additional markers for assessing mRNA vaccine quality.

Simplified

In this study, we tested whether our previously developed biomarker analysis could evaluate the bioactivity of SARS-Cov-2 mRNA vaccines, including their toxicity profiles. We also identified novel biomarkers that could be used to evaluate mRNA vaccine quality by analyzing global gene expression. We administered saline (SA), an influenza hemagglutinin (HA) vaccine, a toxic reference influenza vaccine (RE), and different amounts of an mRNA vaccine (Spikevax or COMIRNATY) to mice, either intraperitoneally or intramuscularly. Sixteen hours post-administration, we analyzed mouse body weight (BW), white blood cell (WBC) count, plasma cytokine levels, and biomarker gene expression in the lungs. Moreover, we performed a comprehensive gene expression analysis using DNA microarrays. BW and WBC count in the mRNA vaccine and RE groups significantly decreased compared with those in the HA group. BW and WBC count between the mRNA vaccine and RE groups did not significantly differ. In contrast, analysis of the expression levels of 15 biomarker genes revealed that 14 of the 15 biomarkers in the Spikevax group and all biomarkers in the COMIRNATY group were significantly upregulated compared with those in the HA group. The expression levels of some biomarkers (Psme1, Trafd1, Lgals9, Mx2) were significantly higher in the mRNA groups than those in the RE group. Furthermore, the mRNA vaccine groups exhibited significantly higher production of inflammatory cytokines than did the HA and RE groups. Global gene expression analysis revealed the gene signature following mRNA vaccination and confirmed that most of our biomarkers were present in the set of genes that were upregulated in the mRNA vaccine groups. In addition, we identified novel genes with significantly increased mRNA expression levels. Our results suggest that this biomarker-based evaluation system is highly sensitive to mRNA vaccine bioactivity and is useful for assessing vaccine safety in the quality control of mRNA vaccines.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

PubMed

New safety test for mRNA vaccines using lung gene markers

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the mrna technology brief

Abstract

Full Text

Funding

Competing interests

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the mrna technology brief